Resveratrol Improves the Progression of Osteoarthritis by Regulating the SIRT1-FoxO1 Pathway-Mediated Cholesterol Metabolism
Open Access
- 4 January 2023
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-13
Abstract
Osteoarthritis (OA) is considered a metabolic disorder. This study investigated the effect of resveratrol (RES) on cholesterol accumulation in osteoarthritic articular cartilage via the silent information regulator 1 (SIRT1)/forkhead transcription factor (FoxO1) pathway. Interleukin (IL)-1β-treated chondrocytes that mimic OA chondrocytes were used in in vitro experiments. The optimal RES concentration was selected based on the results of chondrocyte proliferation in the Cell Counting Kit-8 assay. Western blotting, immunofluorescence, and reverse transcription-quantitative polymerase chain reaction were performed. For the animal experiments, mice were randomly divided into the RES group ( ), medial meniscus destabilization group ( ), and sham group ( ), and each group received the same dose of RES or saline. Articular cartilage tissue was obtained eight weeks after surgery for relevant histological analysis. Clinical tissue test results suggest that downregulation of the SIRT1/FoxO1 pathway is associated with cholesterol buildup in OA chondrocytes. For the in vitro studies, RES increased the expression of SIRT1 and phosphorylation of FoxO1 in IL-1β-treated chondrocytes, promoted the expression of cholesterol efflux factor liver X receptor alpha (LXRα), and inhibited the expression of cholesterol synthesis-associated factor sterol-regulatory element binding proteins 2 (SREBP2). This reduced IL-1β-induced chondrocytes cholesterol accumulation. SIRT1 inhibition prevented the RES-mediated reduction in cholesterol buildup. Inhibiting FoxO1 but not SIRT1 reduced FoxO1 phosphorylation and increased cholesterol buildup in cultured chondrocytes. Additionally, in vivo experiments have shown that RES can alleviate cholesterol buildup and pathological changes in OA cartilage. Our findings suggest that RES regulates cholesterol buildup in osteoarthritic articular cartilage via the SIRT1/FoxO1 pathway, thereby improving the progression of OA.Keywords
All Related Versions
Funding Information
- Department of Science and Technology of Hubei Province (2015BCA316, 81071494)
- National Natural Science Foundation of China (2015BCA316, 81071494)
This publication has 34 references indexed in Scilit:
- High systemic levels of low-density lipoprotein cholesterol: fuel to the flames in inflammatory osteoarthritis?Rheumatology, 2015
- MicroRNA-33a regulates cholesterol synthesis and cholesterol efflux-related genes in osteoarthritic chondrocytesArthritis Research & Therapy, 2015
- Silent information regulator 1 inhibition induces lipid metabolism disorders of hepatocytes and enhances hepatitis C virus replicationHepatology Research, 2013
- Central Role of SREBP-2 in the Pathogenesis of OsteoarthritisPLOS ONE, 2012
- Potential involvement of SIRT1 in the pathogenesis of osteoarthritis through the modulation of chondrocyte gene expressionsJournal of Orthopaedic Research, 2010
- The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the mouseOsteoarthritis and Cartilage, 2010
- Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytesJournal of Orthopaedic Research, 2010
- The FoxO codeOncogene, 2008
- Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylaseThe EMBO Journal, 2004
- Consequences of cellular cholesterol accumulation: basic concepts and physiological implicationsJournal of Clinical Investigation, 2002